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A b s t r a c t
Background: Patients with inferior wall ST segment elevation myocardial infarction (STEMI) are considered to be at lower risk
than patients with anterior wall STEMI. Nonetheless, 30–40% of all acute inferior wall MI cases have a poor prognosis.
Aim: To assess the frequency of ST segment changes (elevation or depression) in lead aVR in inferior STEMI patients, and to
determine the clinical course and short-term prognosis of such patients.
Methods: The study retrospectively analysed the records of 320 consecutive patients with inferior wall STEMI (206 males,
114 females, mean age 65.6 ± 11.1 years). Patients were divided into three groups based on treatment: group A, primary
percutaneous coronary intervention (134 patients); group B, fibrinolytic therapy (96 patients); and group C, conservative
treatment (no reperfusion therapy) (90 patients). The mean time from onset of pain to the first ECG for all patients was 6.1 h.
The total number of in-hospital deaths was 29 (9.0%), comprising 11 (8.2%) in group A, seven (7.3%) in group B, and
11 (12.2%) in group C (NS). The mean maximum creatine phosphokinase was 2,021 ± 1,837 U/L in group A, 1,734 ± 1,581 U/L
in group B, and 1,217 ± 981 U/L in group C (p = 0.01). The mean left ventricular ejection fraction was 50.2% ± 9.0%,
54.9 ± 8.6%, and 51.3% ± 9.7% for groups A, B and C, respectively (NS).
Results: ST segment changes in lead aVR were observed in 135 (42.2%) patients, comprising elevation in 47 (14.7%) patients
and depression in 88 (27.5%) patients. The in-hospital mortality rates for patients with ST segment elevation, ST segment
depression, and no ST segment changes were 27.7%, 16.5%, and 1.0%, respectively (p < 0.001). For group A, the in-hospital
mortality rate was higher in patients with ST segment elevation than in patients with no ST segment changes (15.4% vs 1.2%,
p < 0.001). For group B, the in-hospital mortality rates were 33.3%, 12.9%, and 0%, in patients with ST segment elevation,
ST segment depression, and no ST changes, respectively (p = 0.006). For group C, the in-hospital mortality rate was higher in
patients with ST segment elevation (32%) than in patients with ST segment depression (12.5%) and patients with no
ST segment changes (2%, p = 0.006). Logistic regression analysis found that female gender, diabetes, hypertension, lower
ejection fraction, and cardiogenic shock on admission were independent predictors of ST segment elevation.
Conclusions: ST segment changes in lead aVR occurred in approximately half of inferior wall STEMI patients. The presence
of such ST segment changes was associated with a poorer prognosis during the hospital stay, and the changes were not
associated with the type of reperfusion treatment.
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INTRODUCTION
ST segment elevation myocardial infarction (STEMI) of the
inferior wall is considered to be associated with a lower risk
of MI than STEMI of the anterior wall [1, 2]. Nevertheless,
approximately 30% of patients with inferior wall STEMI expe-
rience complications during their hospital stay which are as-
sociated with a poor prognosis [3–6].
There is a need for non-invasive assessments that enable
clinicians to identify whether an inferior STEMI patient is at a high
risk of complications and/or adverse outcomes. ST segment
changes in lead aVR are typically ignored in electrocardio-
graph (ECG) analysis [7, 8].
According to the European Society of Cardiology (ESC)
guidelines, ST segment elevation in lead aVR is not useful for
the diagnosis of MI. However, publications over the past ten
years have indicated that aVR changes occur in acute coronary
syndrome (ACS) [9, 10]. ST segment elevation in lead aVR in
ACS could indicate stenosis of the left main coronary artery or
three-vessel coronary artery disease (CAD), and is associated
with a poor prognosis. ST segment changes in lead aVR can be
useful in predicting the success of primary percutaneous coro-
nary intervention (PCI) [11–15]. A Japanese study of inferior
wall STEMI found that the grade of ST segment depression cor-
related with impaired reperfusion during PCI [16].
Despite the abovementioned studies, the prognostic si-
gnificance of ST segment elevation in lead aVR in STEMI pa-
tients remains to be established. In particular, little is known
about the incidence of ST segment changes in lead aVR in
inferior wall STEMI patients, nor about the prognostic signifi-
cance of such changes.
The present study examined ST segment changes (eleva-
tion and depression) in lead aVR in inferior wall STEMI pa-
tients. The study determined the frequency of ST segment
changes in such patients, and the relationship between
ST segment changes and short-term clinical outcomes.
METHODS
Study groups
We retrospectively analysed the records of 320 consecutive pa-
tients (206 males, 114 females, mean age 65.6 ± 11.1 years)
who presented with inferior wall STEMI at the Department of
Internal Medicine (Gorlice, Poland) and the Department of Car-
diology and Hypertension (Krakow, Poland) between 2003 and
2006. Patients were divided into three groups based upon the
treatment they had received: group A, invasive treatment with
primary PCI (81 males, 53 females, mean age 66.1 ± 10.6 years);
group B, fibrinolytic therapy (77 males, 19 females, mean age
62.7 ± 12.3 years) because PCI of less than 90 min was not
possible or because written informed consent for invasive treat-
ment was not provided; and group C, conservative treatment
without reperfusion therapy (48 males, 42 females, mean age
67.8 ± 10.9 years) owing to late presentation of symptoms,
duration of infarct pain more or less than 12 h but with contrain-
dication(s) for fibrinolytic therapy, or because written informed
consent for invasive treatment was not provided.
Myocardial infarction and definition of end-points
Demographic parameters and risk factors were analysed for
all groups (Table 1). Myocardial infarction was defined based
on ESC/American College of Cardiology (ACC) guidelines [1]:
(1) duration of pain more than 30 min; (2) a necrotic myocar-
dial marker (troponins or myocardial fraction of creatinine
phosphokinase [CK-MB]) at least twice the upper limit; or
(3) ST segment elevation in two continuous leads II, III, or
aVF of at least 1 mm (60 ms) after the J point.
The duration of infarction pain was defined as the time
from initiation of pain to the time of first medical contact. De-
ath and cardiogenic shock were recorded, and the composite
end-point was defined as death or cardiogenic shock not en-
ding with death. Heart failure was diagnosed based on the pre-
sence of pulmonary rales, pulmonary oedema, chest X-ray, third
heart sound, or peripheral oedema. The presence of a second-
or third-degree atrio-ventricular block (AVB II/III degree), pa-
roxysmal atrial fibrillation (PAF), sustained ventricular tachy-
cardia (VT), and ventricular fibrillation (VF) was also noted.
ECG analysis
The first ECG was analysed at a paper speed of 25 mm/s, and
the time from onset of pain to ECG was recorded. ST seg-
ment changes (elevation or depression) were measured ma-
nually at 60 ms after the J point, and a magnitude of 1 mm
was considered significant. The magnitude of ST segment
Table 1. Patient clinical and demographic characteristics
Group A Group B Group C All patients P*
(n = 134) (n = 96) (n = 90) (n = 320)
Age [years] 66.1 ± 10.6 62.7 ± 12.3 67.8 ± 10.9 65.5 ± 11.3 NS
Gender (women/men) 81/53 77/19 48/42 206/114 NS
Hypertension 83 (61.9%) 40 (41.7%) 36 (40%) 159 (49.7%) NS
Hypercholesterolaemia 91 (67.9%) 50 (52.1%) 49 (54.4%) 190 (59.3%) NS
Smoking 45 (33.6%) 50 (52.1%) 28 (31.1%) 123 (38.4%) NS
Obesity 24 (17.9%) 14 (14.6%) 4 (4.44%) 42 (13.1%) NS
Diabetes mellitus 25 (18.7%) 17 (17.7%) 12 (13.3%) 54 (16.9%) NS
*p — group A vs group B vs group C
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changes in lead aVR was relative to the TP segment as a base-
line. The characteristics of ST segment changes in the II, III,
aVF, and aVR leads were analysed.
Statistical analysis
Categorical variables are expressed as numbers or percenta-
ges of patients, and continuous variables as medians ± SD.
For comparison of categorical variables, the c2 test or the
c2 test with Yates’ correction if appropriate was used. The
Mann-Whitney test was used for comparison of numerical
variables. All clinical and demographic variables underwent
logistic regression analysis to identify independent predictors
of ST segment elevation. Odds ratios and 95% confidence
intervals were calculated. A two-tailed p value of less than
0.05 was considered to indicate significance. Analyses were
performed using Statistica PL software (StatSoft 8.0, StatSoft
Polska, Krakow, Poland).
RESULTS
Of the total of 320 patients, 230 underwent reperfusion the-
rapy (72%, 160 males). One hundred and thirty four patients
underwent primary PCI treatment (group A), 96 patients un-
derwent fibrinolytic therapy (group B), and 90 patients un-
derwent conservative treatment (group C). The time from pain
onset to first medical contact was 6.1 ± 3.5 h for the overall
320 patients, 4.0 ± 3.7 h for group A, 3.5 ± 2.8 h for group B,
and 8.6 ± 4.5 h for group C (p < 0.04 for group A vs group C
and for group B vs group C).
During hospitalisation, 29 (9.0%) deaths occurred, with
11 (8.2%) in group A, seven (7.3%) in group B, and 11 (12.2%)
in group C (p > 0.05). The maximal creatine phosphokinase
(CPK) levels in groups A, B, and C were 2,021 ± 1,837 U/L,
1,734 ± 1,581 U/L, and 1,217 ± 981 U/L, respectively
(p = 0.01 for group A vs group C).
There were ST segment changes in lead aVR in 135
(42.2%) patients. Those changes comprised elevation in 47
(14.7%) patients and depression in 88 (27.5%) patients.
The in-hospital mortality rates of patients with ST seg-
ment elevation, ST segment depression, and no ST segment
changes were 27.7%, 16.5%, and 1.0%, respectively (p <
< 0.001; Fig. 1). The percentage of patients with ST segment
elevation, ST segment depression, and with no ST segment
change who reached the composite end-point (death or car-
diogenic shock) was 31.9%, 27.0%, and 3.2%, respectively
(p < 0.001).
Patients with ST segment depression in lead aVR had
higher CPK levels than patients with ST segment eleva-
tion in lead aVR (max. CPK: 2,375 ± 2,012 vs 1,342 ±
± 1,342 U/L, p = 0.003), and higher CPK than patients
with no changes in lead aVR (max. CPK: 2,375 ± 2,012 vs
1,563 ± 1,422 U/L, p = 0.0045). Logistic regression ana-
lysis identified age, infarct localisation, ejection fraction,
cardiogenic shock on admission, VF/VT, AVB III degree,
diabetes mellitus and ST segment changes (elevation or de-
pression) in lead aVR as independent predictors of in-
-hospital mortality (Table 2).
Figure 1. The relationship between ST segment changes in lead
aVR and in-hospital mortality
Table 2. Logistic regression analysis of independent predictors of in-hospital mortality
Variable 95% confidence interval Odds ratio P
Gender 0.77–4.1 1.78 0.17
Age 1.01–1.09 1.05 0.017
Ventricular tachycardia/ventricular fibrillation 1.51–11.75 4.2 0.006
Diabetes 1.08–5.83 2.53 0.032
AV block III degree 1.35–8.16 3.31 0.009
Cardiogenic shock 8.55–52.58 21.2 0.00000
Heart failure 0.95–4.63 2.1 0.06
Creatine phosphokinase 0.99–1.00 0.99 0.83
Left ventricular ejection fraction [%] 0.85–0.98 0.92 0.01
ST segment changes in lead aVR 5.46–101.61 23.56 0.000003
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Outcomes according to therapy
and ST segment changes
In group A, 51 (38%) patients had ST segment changes in
lead aVR, comprising elevation in 13 (9.7%) patients and de-
pression in 38 (28.3%) patients; there was no ST segment
change in 83 (61.9%) patients. The in-hospital mortality rates
were higher for ST segment elevation patients and for ST seg-
ment depression patients than for patients with no ST seg-
ment changes in lead aVR (Fig. 2).
In group B, 43 (44.8%) patients had ST segment chan-
ges in lead aVR, comprising elevation in nine (9.4%) patients
and depression in 34 (35.4%) patients; there was no ST seg-
ment change in 53 (55.2%) patients. The in-hospital morta-
lity rate for patients with ST segment elevation was higher
than that for patients with ST segment depression and for
patients with no ST segment changes (Fig. 3). The percenta-
ge of patients who reached the composite end-point (death
or cardiogenic shock) was greater in patients with ST seg-
ment elevation (33.3%) than in patients with ST segment
depression (25.8%) or patients with no ST segment changes
(3.6%, p = 0.002 for all).
In group C, 41 (45.6%) patients had ST segment chan-
ges in lead aVR, comprising elevation in 25 (27.8%) patients
and depression in 16 (17.8%) patients, and no ST segment
changes were observed in 49 (54.4%) patients. The in-ho-
spital mortality rate of patients with ST segment elevation
was higher than that for patients with ST segment depres-
sion and for patients with no ST segment changes (Fig. 4).
The percentage of patients who reached the composite end-
-point was greater in patients with ST segment elevation
(36%) than in patients with ST segment depression (25%)
and patients with no ST segment changes in lead aVR (4%,
p = 0.002 for all).
Clinical parameters and
ST segment changes in lead aVR
Logistic regression analysis showed that the independent pre-
dictors of ST segment elevation in lead aVR were female gen-
der, diabetes, hypertension, lower ejection fraction, and car-
diogenic shock on admission (Table 3).
DISCUSSION
The use of fibrinolytics to treat inferior wall STEMI is associa-
ted with a mortality rate of 2–9% [17–19]. However, almost
all large clinical trials have shown that fibrinolytic treatment
of inferior wall MI has no effect on mortality [3, 17–19]. In
ECG analysis, all leads except aVR are considered for reco-
gnition of MI and localisation of STEMI [20].
ST segment depression in lead aVR
Several studies have examined ST segment changes in lead
aVR in inferior wall STEMI [16, 21–25]. Senaratne et al. [25]
found that patients with inferior wall STEMI more com-
Figure 4. The relationship between ST segment changes in lead
aVR and the mortality of patients not treated with reperfusion
therapy (group C)
Figure 3. The relationship between ST segment changes in lead
aVR and in-hospital mortality of patients treated with fibrinoly-
sis (group B)
Figure 2. The relationship between ST segment changes in lead
aVR and in-hospital mortality of patients treated with primary
percutaneous coronary intervention (group A)
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monly presented with ST segment depression in lead aVR
than patients with anterior wall STEMI (20.6% vs 5.8%,
p < 0.05). In the present study of inferior wall STEMI, we
found that ST segment depression was present in 26.6% of
patients.
We found that patients with ST segment depression in
lead aVR had a higher CPK level compared to patients with
no ST segment depression in lead aVR (2,375 ± 2,012 vs
1,563 ± 1,422 U/L, p = 0.004). Senaratne at al. [25] found
that although patients with inferior STEMI (181 patients) with
ST segment depression in lead aVR appeared to have a hi-
gher CPK level compared to patients with no ST segment
depression in lead aVR, statistical analysis showed that the
levels were not significantly different (2,196 ± 368 U/L vs
1,566 ± 151 U/L, p = 0.79). It may be that the difference
would have become significant if a larger number of patients
had been used in that study.
In the present study, patients with ST segment depres-
sion in lead aVR had higher rates of death (16.5% vs 1.0%),
composite end-point (27.0% vs 3.2%) and VF (12.1% vs 4.8%)
than patients with no ST segment changes in lead aVR
(p < 0.001 for all). Moreover, that trend was independent of
the type of therapy.
ST segment depression in lead aVR is poorly characteri-
sed. Recent publications suggest that this phenomenon re-
flects ischaemia or injury in the region of the apex and/or the
infero-lateral area [16, 21, 22, 24, 25]. Those areas are sup-
plied with blood from the postero-lateral branch of the cir-
cumflex artery or an AV branch of the right coronary artery.
In a study of patients diagnosed with inferior wall STEMI wi-
thin 6 h of the onset of pain, Kosuge at al. [16] reported that
ST segment depression in lead aVR was associated with im-
paired coronary perfusion despite thrombolysis in myocar-
dial infarction grade 3 (TIMI-3) after primary PCI.
One study reported that the magnitude of ST segment
depression in lead aVR was a strong predictor of impaired myo-
cardial perfusion after successful primary PCI according to
multivariate regression analysis [24]. ST segment depression in
lead aVR could indicate impaired tissue perfusion, which is
associated with poor prognosis even in patients with TIMI-3
flow after primary PCI [24]. It is likely that patients in the study
by Kosuge et al. [24], as with the patients in our present study,
had ST segment depression in lead aVR that correlated with
a larger area of MI (hence the higher CPK levels), an event that
is associated with a range of complications.
ST segment elevation in lead aVR
No previous study has examined ST segment elevation in
lead aVR in inferior wall STEMI. However, there have been
studies concerning the prognostic significance of ST segment
changes in lead aVR in patients with non ST segment eleva-
tion myocardial infarction (NSTEMI) or anterior wall STEMI
[13, 15, 26–29]. In our present study, we observed higher rates
of death (27.7% vs 1.0%, p < 0.001), composite end-point
(1.9% vs 3.2%, p < 0.001), VF (12.8% vs 4.8%, p < 0.045)
and III degree AVB (21.3% vs 8.5%, p < 0.01) in patients
with ST segment elevation compared to patients with no
ST segment changes. Those trends were observed regardless
of the type of reperfusion therapy. In our study population,
three-vessel disease occurred in 33% of patients with
ST segment elevation in lead aVR. The poor prognosis of
the present patients who had ST segment elevation may be
partly due to this high incidence of three-vessel CAD.
What influences ST segment
elevation in lead aVR?
Our study found an association between hypertension and
ST segment elevation in lead aVR (Table 1). Similarly, Rostoff
and Piwowarska [26] showed that patients with ACS ST seg-
ment elevation in lead aVR were more likely to have hyper-
tension. We also found that ST segment elevation was asso-
ciated with female gender, diabetes, lower ejection fraction,
and cardiogenic shock on admission (Table 1). Recent publi-
cations showed that ST segment elevation in lead aVR was
Table 3. Logistic regression analysis of independent predictors of ST segment elevation in lead aVR
Variable 95% confidence interval Odds ratio P
Gender 2.1–53.2 10.8 0.003
Smoking 0.07–1.75 0.35 0.20
Obesity 0.04–3.5 0.41 0.41
Diabetes 1.12–13.44 4.7 0.032
Hypertension 1.04–125.24 11.4 0.043
Cardiogenic shock 1.2–184.19 14.9 0.032
Heart failure 0.53–6.36 1.8 0.32
Creatine phosphokinase 0.99–1.00 1.0 0.89
Left ventricular ejection fraction [%] 0.88–1.00 0.94 0.84
Multivessel coronary disease 0.17–2.10 0.61 0.43
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associated with three-vessel CAD or with left main disease,
both of which predispose patients to cardiogenic shock in
MI. The present study also found that diabetes and decre-
ased left ventricular ejection fraction were associated with
ST segment elevation, and both of those factors are well-
-known indicators for cardiogenic shock in MI. We found that
female patients with ST segment elevation had poorer pro-
gnoses than male patients. This may be because women expe-
rience MI at an older age than men, and age is associated
with an increased risk of death. Alternatively, women often
have more accompanying disorders (e.g., hypertension, dia-
betes and obesity) that are risk factors.
Clinical significance of
ST segment changes in lead aVR
The present study found that analysis of ST segment changes
in lead aVR in inferior wall STEMI patients provided informa-
tion that would assist in the classification of patient risk and
prognosis. In particular, our study showed that patients with
ST segment elevation or depression have a poor prognosis.
Importantly, we also found that the incidence of ST segment
changes in lead aVR did not depend on the reperfusion stra-
tegy (i.e., mechanical vs pharmacological). Based on these
findings, we would classify a patient with inferior wall STEMI
as being at high risk when an ECG shows ST segment chan-
ges (elevation or depression) in lead aVR. We suggest that
such patients should be treated with primary PCI. It should
be noted that even if the invasive therapy is successful, such
patients still have an increased risk of death due to acute MI.
Limitations of the study
We found that mortality rates were similar for the two reper-
fusion groups. This may have been due to: (1) the large num-
ber of complications that occurred during hospitalisation, in-
cluding cardiogenic shock, in the primary PCI group; (2) the
time from onset of pain to treatment being only 3.5 h for the
fibrinolytic group, which could be associated with their favo-
urable prognosis; and/or (3) the sample sizes being too small
to detect significant differences. Furthermore, the study only
included inferior wall STEMI patients; as large clinical trials
have shown, there is no benefit of fibrinolytic therapy over
placebo, and no benefit of primary PCI over fibrinolysis du-
ring the hospital stay or in terms of long-term mortality in
these patients [30, 31].
CONCLUSIONS
ST segment changes in lead aVR were present in approxima-
tely half of all inferior wall STEMI patients, with depression
being more common than elevation. Those ST segment chan-
ges were found to be associated with a poor prognosis during
the hospital stay. Finally, patient outcomes were not influen-
ced by the type of reperfusion treatment.
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Znaczenie prognostyczne zmian odcinka ST
w odprowadzeniu aVR u chorych z zawałem
ściany dolnej z uniesieniem odcinka ST
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S t r e s z c z e n i e
Wstęp: Zawał serca z uniesieniem odcinka ST (STEMI) ściany dolnej uznaje się za zawał niskiego ryzyka, mimo że 30–40%
zawałów ściany dolnej to zawały wysokiego ryzyka związane z gorszym rokowaniem. Wyniki ostatnich badań sugerują, że obec-
ność uniesienia odcinka ST w odprowadzeniu aVR wiąże się z przebiegiem klinicznym zawału serca bez uniesienia odcinka ST.
Cel: Celem pracy było ustalenie, czy zmiany odcinka ST w odprowadzeniu aVR mają związek z rokowaniem krótkotermino-
wym i przebiegiem klinicznym STEMI ściany dolnej w zależności od metody leczenia reperfuzyjnego.
Metody: Do analizy retrospektywnej włączono 320 kolejnych chorych z zawałem ściany dolnej, 206 mężczyzn i 114 kobiet,
w średnim wieku 65,6 ± 11,1 roku. Chorych podzielono na 3 grupy: Grupa A — leczona inwazyjnie za pomocą pierwotnej
angioplastyki wieńcowej (PCI) (n = 134; 81 mężczyzn i 53 kobiet, śr. wiek 66,1 ± 10,6 roku); Grupa B — leczona fibryno-
litycznie (n = 96; 77 mężczyzn i 19 kobiet, śr. wiek 62,7 ± 12,3 roku); Grupa C — bez leczenia reperfuzyjnego (n = 90;
48 mężczyzn i 42 kobiety, śr. wiek 67,8 ± 10,9 roku). Leczenie reperfuzyjne zastosowano u 230 (72%) chorych. Czas od
początku wystąpienia bólu zawałowego do wykonania EKG wynosił 6,1 h. Podczas obserwacji szpitalnej stwierdzono łącznie
29 (9,0%) zgonów, w grupie A — 11 (8,2%), w grupie B — 7 (7,3%), a w grupie C — 11 (12,2%) (p = NS). Maksymalne
stężenie kinazy fosfokreatynowej wynosiło 2021 ± 1837 j./l w grupie A, 1734 ± 1581 j./l w grupie B oraz 1217 ± 981 j./l
w grupie C (p = 0,01). Frakcja wyrzutowa lewej komory wynosiła odpowiednio: 50,2% ± 9,0%; 54,9% ± 8,6% i 51,3% ±
± 9,7% (p = NS).
Wyniki: Zmiany odcinka ST w odprowadzeniu aVR obserwowano łącznie u 135 (42,2%) chorych, w tym uniesienie odcin-
ka ST u 47 (14,7%), a obniżenie odcinka ST u 88 (27,5%) pacjentów. Śmiertelność była istotnie wyższa w grupie osób
z uniesieniem odcinka ST w odprowadzeniu aVR (13 chorych; 27,7%) w porównaniu z grupą z obniżeniem odcinka ST
(14 chorych; 16,5%) oraz z grupą bez zmian odcinka ST w aVR (2 chorych; 1%); p < 0,001. W grupie A zanotowano
znamiennie większą śmiertelność u chorych z uniesieniem odcinka ST w aVR w porównaniu z pacjentami bez zmian odcinka
ST w odprowadzeniu aVR (15,4% v. 1,2%; p < 0,001). W grupie B śmiertelność wewnątrzszpitalna wynosiła: 33,3%, 12,9%
i 0% (p = 0,006), w grupie C — 32,0%; 12,5% i 2% (p = 0,006), odpowiednio u chorych z uniesieniem odcinka ST,
obniżeniem odcinka ST i brakiem zmian odcinka ST w odprowadzeniu aVR. W analizie regresji wieloczynnikowej niezależ-
nymi predyktorami uniesienia odcinka ST były: płeć żeńska, cukrzyca, nadciśnienie tętnicze, niższa frakcja wyrzutowa,
wstrząs kardiogenny przy przyjęciu.
Wnioski: Zmiany odcinka ST w odprowadzeniu aVR, zarówno uniesienie, jak i obniżenie, są częste w STEMI ściany dolnej
i występują łącznie u prawie połowy chorych. Obecność zmian odcinka ST w odprowadzeniu aVR w zawale ściany dolnej
wiąże się z gorszym rokowaniem w trakcie hospitalizacji niezależnie od rodzaju terapii i rodzaju zastosowanego leczenia
reperfuzyjnego.
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